Exelixis Inc (EXEL)

$19.13 0.10 (0.53%)

16:00 EDT EXEL Stock Quote Delayed 30 Minutes

7 Biotech Stocks That Will Make You Rich in 10 Years

By Josh Enomoto, InvestorPlace Contributor Jan 18, 2023

Although the health innovation space presents risks, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.

7 Undervalued Biotech Stocks to Buy Before They Boom

These 7 Biotech Stocks Are Set to Boom in 2023

3 Biotech Stocks to Buy Now for Extraordinary Gains

Volume:

Previous Close -

Market Cap 6.03B

PE Ratio 73.58

EPS 0.26

Volume (Avg. Vol.) 1.60M

Day's Range $18.97 - $19.30

52-Week Range $14.87 - $22.47

Dividend & Yield N/A (N/A)

EXEL Stock Predictions, Articles, and Exelixis Inc News

From InvestorPlace
From the Web

The 7 Best Biotech Stocks to Buy

By Dana Blankenhorn, InvestorPlace Contributor Sep 20, 2022

The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer May 24, 2022

Good morning, trader! We're jumping into trading on Tuesday with an overview of the biggest pre-market stock movers this morning!

7 Top-Rated Biotech Stocks to Buy for Q2

By Louis Navellier and the InvestorPlace Research Staff Apr 21, 2022

In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill.

7 of the Best Cheap Stocks Under $20 for 2022 to Buy Now

By Muslim Farooque, InvestorPlace Contributor Jan 3, 2022

These cheap stocks are trading at highly attractive prices and have the potential to break through this year.

7 Best Biotech Stocks to Buy in 2021 with Huge Upside

By Alex Sirois Aug 25, 2021

Biotech stocks are worth considering. Risk aside, big pharma firms can still produce big pharma returns at the end of the day.

3 Mid-Cap Growth Stocks to Buy

By Chris Tyler, InvestorPlace Contributor Feb 12, 2020

It’s time to look past the obvious FOMO and focus on smarter mid-cap growth stocks to power your portfolio higher

7 Under-The-Radar Growth Stocks That Could Benefit New Investors

By Will Healy, InvestorPlace Contributor Oct 14, 2019

These 7 growth stocks remain positioned for significant future increases, and could bring huge returns to new investors for years to come.

10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar

By James Brumley, InvestorPlace Feature Writer Aug 21, 2019

Qorvo, Catalent and XPO Logistics are just some of the up-and-coming stocks too many investors are still overlooking.

8 Biotech Stocks to Watch After the Q2 Earnings Season

By Chris Lau, InvestorPlace Contributor Aug 20, 2019

Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.

Risk-Tolerant Investors, Turn Your Eyes to Exelixis Stock

By Chris Tyler, InvestorPlace Contributor Apr 11, 2019

Smaller-capitalization biotechs can be riskier investments, but EXEL stock has more than just promise off and on the price chart and is readying to be purchased.

5 Beaten-Down Biotech Stocks to Pick Up from the Wreckage

By Aaron Levitt, InvestorPlace Contributor Oct 17, 2018

After the market's rout, biotech stocks offer a huge value right now. Here are 5 that offer the best opportunities for investors.

7 Biotech Stocks to Buy Now

By Chris Lau, InvestorPlace Contributor Sep 19, 2018

Biotech companies are recovering nicely this year. With a quarter left to go, the upside potential is high for those biotech stocks that dipped recently.

8 Undervalued Biotech Stocks to Watch

By Josh Enomoto, InvestorPlace Contributor Aug 20, 2018

Volatility across all categories of biotech stocks makes this present juncture an ideal time to consider picking up undervalued names.

Trade of the Day: Exelixis, Inc. (EXEL)

By Ken Trester May 18, 2018

My indicators are giving bullish-to-neutral readings this week, a mild downgrade from bullish readings last week. The ratio of advancing issues to declining issues is not as strong as I would like to see.